A B S T R A C T Bradykinin receptors on cultured human fibroblasts were characterized using [2,3-prolyl-3,4-3H(N) PGFia. This system, the first in which bradykinin receptors on human cells have been characterized, should prove useful for investigation of the regulation of bradykinin-influenced biological processes.
A B S T R A C T Bradykinin receptors on cultured human fibroblasts were characterized using [2,3-prolyl-3,4-3H(N)]bradykinin as radioligand. During incubation with intact fibroblasts, intact [3H]bradykinin was lost much more rapidly at 370 than at 4°C as determined by bioassay, high-performance liquid chromatography, and ion-exchange chromatography, and is likely to be degraded. At 40, but not at 37°C, bradykinin remained intact in the presence of 2 mM bacitracin, but not in the presence of soybean trypsin inhibitor or SQ-20881, an inhibitor of kininase II. Specific binding at 4°C was saturable with a maximum number of binding sites of 230±18 fmol/mg protein (mean±SE, n = 4) and a dissociation constant of 4.6±0.5 nM (mean±SE, n = 4). Linear Scatchard plots, Hill coefficients close to unity (0.95-1.06), and the failure of excess bradykinin to influence dissociation kinetics are consistent with a single component binding system with no significant cooperativity. Na+ at physiological concentrations and Ca++ or Mg++ at 3-10 mM reduced binding by 25%. The relative potencies of bradykinin analogues and unrelated peptides in competing for [3H]bradykinin binding indicated a specificity of the binding sites consistent with that of a B2 type receptor. Potencies of the peptides in displacing [3H]bradykinin correlated with their abilities to release prostacyclin, determined as its metabolite 6-ketoPGFia. This system, the first in which bradykinin receptors on human cells have been characterized, should prove useful for investigation of the regulation of bradykinin-influenced biological processes. INTRODUCTION The nonapeptide bradykinin is involved in many important biological processes including inflammation (1) and the regulation of blood pressure (2, 3) , electrolyte fluxes, and fluid balance (4, 5) . Recent evidence suggests that bradykinin might also have a role as a central neurotransmitter (6) . From indirect experimental approaches (structure-activity relationships, kinetic data), it has been concluded that bradykinin exerts its characteristic effects by interacting with one or more types of specific receptors on the cell surface (7) (8) (9) . Recently, using 1251-[Tyrl]kallidin (10) or [3H]bradykinin (5, 11) as radioligands, bradykininbinding sites with properties of physiologic bradykinin receptors have been identified in crude membrane preparations from several mammalian tissues. In intact tissues, bradykinin receptor stimulation appears to initiate a series of intracellular events, including activation of phospholipases A2 and C (12, 13) , the release of prostaglandins (PG)' (14) (15) (16) , and accumulation of cyclic (c)AMP and cyclic guanosine monophosphate (16, 17) . A variety of experimental manipulations, such as treatment of intact cells and tissues with steroids (12), PGE2 (18) , serotonin (18) , trypsin (19) , neuraminidase (20) , and thiol compounds (21) , have been shown to alter their responsiveness to bradykinin. Proper interpretation of the events that regulate bradykinin responsiveness, however, requires an understanding of the interaction between bradykinin and its receptor, receptor-effector coupling systems, and biological effects of bradykinin. This goal can best be achieved in an intact cell system that retains receptor-mediated biological responses. Cultured human skin fibroblasts have frequently been used to investigate hormone effects and genetic defects. Human fibroblasts also have been proven to be a bradykinin-responsive target tissue (12, 16, 22 (24) and concentrations of CaCl2, MgCl2, and MgSO4 reduced by half) supplemented with 0.05% bovine albumin, minimal essential medium amino acid mixture, 2 mM bacitracin, and 10 mM Hlepes, pH 7.3. Binding was initiated by replacing medium with 2 ml of fresh medium containing the appropriate concentrations of [3H]bradykinin with or without 3 MM unlabeled bradykinin. This concentration of bradykinin was determined to be optimal for differentiating specific from nonspecific binding (Fig. 6 B) . At the indicated time thereafter, the medium was removed and cells were rapidly rinsed four times with a total of 20 ml of ice-cold modified HBSS containing 0.2% bovine albumin (pH 7.3). Cells were then rinsed twice with Dulbecco's phosphate-buffered saline, incubated with 2 ml of 0.1% trypsin (10 min, 37°C), and quantitatively transferred to vials for radioassay after addition of 15 ml of Aquasol (New England Nuclear). (Fig. 5 A) . Although the protein content of different subcultures varied (320-450 Mig protein/dish), in a single experiment, the variation in protein per culture dish was <5%. Protein was measured according to Lowry et al. (25) .
Bioassay of intact [3H]bradykinin by binding to fibroblasts. The integrity of [3H]bradykinin in the incubation medium after exposure to fibroblasts (used medium) was tested by its ability to bind specifically to fresh fibroblasts. Used media were transferred to chilled tubes and frozen immediately. For each experimental condition, medium containing the same amount of [3H]bradykinin was prepared and treated identically but was not incubated with cells (control medium). Fibroblasts grown in multi-dish trays were used as a bioassay system. Media (control and used) were thawed (at 0°-4°C) and kept on ice; samples containing the same amounts of radioactivity were incubated with fibroblasts for 30 min at 4°C for determination of specific [3H]bradykinin binding; the difference between specific binding from control and used media was taken as the amount of [3H]bradykinin degraded or altered in such a way that precluded binding to fibroblasts.
Ion-exchange chromatography. To separate intact bradykinin from degraded/altered products, a modification of a previously described procedure was used (26) . 
High-performance liquid chromatography (HPLC).
Fractions eluted from CM-Sephadex were lyophilized and reconstituted in 200 Ml acetonitrile. Aliquots (50 Ml) of the radioactive material were coinjected with nonradioactive standards (-2 Mg) of Lys-bradykinin and des-Arg9-bradykinin and chromatographed on a micro-Bondapack C18 column using a Varian model 5000 liquid chromatograph (Varian Associates, Inc., Instrument Group, Palo Alto, CA) (flow rate, 1 ml/min; isocratic elution for 50 min with a mixture of 80% solvent A [0.05% trifluoroacetic acid, 0.25% triethanolamine] and 20% solvent B [0.05% trifluoroacetic acid, 0.25% triethanolamine, 80% acetonitrile]). The UV absorption of the column effluent was monitored continuously with a variable wavelength spectrophotometer at 210 nm. Portions of each 1-ml fraction were assessed for radioactivity by liquid scintillation counting.
Radioimmunoassay of 6-keto-PGFIa. Incubation medium was assayed directly for 6-keto-PGFIa by a modification of the radioimmunoassay of Yaffe et al. (27) . Each assay contained 100 MI of medium or standard (10-2,000 pg), 50 Ml of 6-keto-PGF1,< (7,000 cpm), 50 Ml of antiserum (diluted such that '40% of the radioligand was bound) and 0.1% of gelatin in a total volume of 400 Ml of 10 mM Tris/ 150 mM NaCl, pH 7.4. After incubation for 16 h at 4°C, antibody-bound 6-keto-PGF<,, was separated from uncomplexed tracer by the addition of 500 MA of an ice-cold 0.5% charcoal/0.05% dextran mixture and tubes were centrifuged (1,000 g, 10 min, 4°C). The supernatants were decanted into scintillation vials for radioassay of antibody-bound 6-keto- [3H]PGFI0 after addition of 10 (Fig. 2) . Identification of this material as bradykinin was confirmed by HPLC (Fig. 3) . Of the radioactivity in medium after incubation of [3H]bradykinin with cells for 2 h at 4°C with bacitracin, 90% was capable of binding to fresh fibroblasts and 86% eluted from CM-Sephadex as authentic bradykinin (Fig. 2 ). After incubation with cells for 1 h at 37°C, however, only 24% bound to fresh fibroblasts and 30% eluted as authentic bradykinin (Fig. 2) . Most of the radioactivity was eluted with 0.2 M ammonium acetate, pH 5.0 (Fig. 2) . As seen in Fig.  3 replaced by equimolar N-methyl-D-glucamine (24) and with the concentrations of Mg++ and Ca++ reduced by half.
Characteristics and specificity of binding of [3H]bradykinin to intact fibroblasts
Binding of [3H]bradykinin by fibroblasts reached apparent equilibrium within 1 h at 4°C (Fig. 4) (Fig. 5) . At 37°C, dissociation was extremely rapid, displaying an upwardly concave curve. Dissociation at either temperature was unaffected by the addition of 3 uM unlabeled bradykinin. In the experiment presented in Fig. 5 , >90% of the cell-associated radioactivity at zero time and after 90 min at 4°C was extracted by brief treatment with acetic acid. This procedure (28, 29 ) is reported to discriminate between surface-bound and internalized ligands. Only 50% of the radioactivity remaining after 40 min at 37°C was extracted with acetic acid, suggesting that some of the bound radioligand had shifted to an acid-resistant compartment during incubation at 370C (29) .
Because apparent equilibrium of binding was not attained at 370C and since [3H]bradykinin was extensively altered/degraded and apparently transferred from the cell surface to another cell-associated compartment at this temperature, most binding studies were performed for 2 h at 40C, where alteration and internalization of this radioligand were minimal. Specific binding (comprising >95% of total binding) was saturated at 20 nM [3H]bradykinin (Fig. 6 A) . Scatchard analysis (30) of these data (Fig. 6 B) (Fig. 6 B) , and Hill plots (31) of equilibrium binding data (Fig. 6 B, inset) (Fig. 7 B) . Lys-bradykinin, Met-Lys-bradykinin, Tyr-bradykinin, and [Tyr8]-bradykinin were able to displace specifically bound hormone to the same extent as bradykinin, provided their concentrations were high enough. Des-Arg9-bradykinin, the product of kininase I action, and the unrelated peptides antiotensin II, neurotensin, and histamine failed to inhibit [3H]bradykinin binding significantly.
The ability of the peptides to stimulate release of PGI2 from fibroblasts was also assessed (Fig. 7 A, Table  III ). The rank order of potency was the same for binding and PGI2 release (bradykinin > Lys-bradykinin > Met-Lys-bradykinin _ Tyr-bradykinin > Tyr8-bradykinin > Tyr5-bradykinin > angiotensin II _ desArg9-bradykinin) ( Table III) .
As seen in these and other (unpublished) experiments, the EC50 values for bradykinin and analogues in stimulating production of PGI2 (i.e., the concentration of bradykinin and analogues that produces halfmaximal stimulation of prostaglandin formation) were greater, by at least an order of magnitude, than the Kd for bradykinin binding or concentrations of the more potent analogues to displace [3H]bradykinin. Although the reasons for this discrepancy are not completely understood, it should be emphasized that PGI2 production was measured at 370C in the absence of bacitracin (in our hands, radioimmunoassay of 6-ketoPGF2af was unreliable in the presence of bacitracin).
DISCUSSION
Bradykinin causes accumulation of cAMP in cultured human fibroblasts apparently as a result of enhancing PG production (16) . Several experimental manipulations (12, 18, 19, 21) can influence the magnitude of these biological responses to bradykinin. To determine whether alterations in specific bradykinin receptors are involved in the changes in responsiveness, it was necessary to establish conditions for assay of bradykinin receptors on the intact cells that retain receptor-mediated biological responses. Before a quantitative analysis of bradykinin binding, it was necessary to evaluate the integrity of bradykinin during incubation with the fibroblasts. During incubation with fibroblasts, especially at 37°C, intact (functional) bradykinin was rapidly lost as assessed by several criteria. At 37°C, bradykinin was rapidly altered so as to preclude binding to fresh fibroblasts and to be readily separated from authentic bradykinin during HPLC and ion-exchange chromatography. Loss 
